Decreased Neutrophil-to-lymphocyte Ratio in Patients with Vitiligo: National Data Analysis

Authors

  • Sarah Weissmann Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; Clinical Research Unit, Soroka University Medical Center, Beer Sheva, Israel
  • Amit Shira Babyev Clinical Research Unit, Soroka University Medical Center, Beer Sheva, Israel
  • Michal Gordon Clinical Research Unit, Soroka University Medical Center, Beer Sheva, Israel
  • Inbal Golan-Tripto Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; Pediatric Pulmonary Unit, Soroka University Medical Center, Beer Sheva, Israel
  • Amir Horev Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; Pediatric Dermatology Service, Soroka University Medical Center, Beer Sheva, Israel

DOI:

https://doi.org/10.2340/actadv.v104.35406

Keywords:

vitiligo, national data, neutrophil-lymphocyte-ratio

Abstract

Vitiligo is characterized by depigmented skin lesions involving melanocyte defects and immune dysregulation. Haematological markers like neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been explored in various skin disorders. Given vitiligo’s proposed pathogenesis, we hypothesized differences in NLR and PLR in vitiligo patients compared to controls. In a national retrospective cohort study (2005–2020) in Israel, blood count data from patients diagnosed with vitiligo (ICD-10 codes) were analysed, excluding patients with recent infections, surgeries, or malignancies. Controls matched for age and sex were selected. Sub-analyses examined age groups, treatment type, and matched controls. Children (n = 3,796) and adults (n = 38,608) with vitiligo showed significant differences in gender distribution, cell counts, and ratios. Vitiligo patients (n = 38,358) exhibited lower NLR, decreased neutrophils and platelets, and increased lymphocytes compared with controls. Non-systemically treated vitiligo patients (n = 33,871) displayed lower NLR and neutrophils compared with matched controls. Systemically treated vitiligo patients (n = 4,487) showed lower NLR, higher PLR, and reduced lymphocytes. Logistic regression identified associations between increased lymphocyte and platelet counts and being systemically treated. This study highlights significant haematological differences in vitiligo patients, emphasizing the potential utility of NLR as an accessible tool for vitiligo assessment. Further investigations are warranted to elucidate the roles of neutrophils and lymphocytes in vitiligo pathogenesis.

Downloads

Download data is not yet available.

References

Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associa-tions, histopathology, etiology, and work-up. J Am Acad Dermatol 2011; 65: 473–491.

https://doi.org/10.1016/j.jaad.2010.11.061

Rashighi M, Harris JE. Vitiligo pathogenesis and emerging treatments. Dermatol Clin 2017; 35: 257–265.

https://doi.org/10.1016/j.det.2016.11.014

Awad SS, Tadros E. Understanding the role of lymphocytes in vitiligo. Int J Immunol Im-munother 2021; 8: 060.

https://doi.org/10.23937/2378-3672/1410060

Alan S, Tuna S, Türkoğlu EB. The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behçet’s syndrome. Kaohsiung J Med Sci 2015; 31: 626–631.

https://doi.org/10.1016/j.kjms.2015.10.010

Marra A, Bondesan A, Caroli D, Grugni G, Sartorio A. The neutrophil to lymphocyte ratio (NLR) positively correlates with the presence and severity of metabolic syndrome in obese adults, but not in obese children/adolescents. BMC Endocr Disord 2023; 23: 121.

https://doi.org/10.1186/s12902-023-01369-4

Tekin R, Aktar F, Yılmaz K, Tekin S, Ayaz C. Comparison of inflammatory markers between adult and pediatric brucellosis patients. Rev Soc Bras Med Trop 2020; 53: e20190356.

https://doi.org/10.1590/0037-8682-0356-2019

Karagun E. An investigation of the relationship between involvement sites in vitiligo pati-ents and autoimmune diseases and hematological parameters. Int J Innov Res Med Sci 2019; 4: 570–573.

https://doi.org/10.23958/ijirms/vol04-i10/769

Solak B, Dikicier BS, Cosansu NC, Erdem T. Neutrophil to lymphocyte ratio in patients with vitiligo. Postepy Dermatol Alergol 2017; 34: 468–470.

https://doi.org/10.5114/ada.2017.71114

Starkebaum G. Chronic neutropenia associated with autoimmune disease. Semin He-matol 2002; 39: 121–127.

https://doi.org/10.1053/shem.2002.31918

Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes 2017; 10: 12.

https://doi.org/10.1186/s13104-016-2335-5

Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Berg J, -Auböck J. Lymphocyte imbalance in vitiligo patients indicated by -elevated CD4+/CD8+ T-cell ratio. Wien Med Wochenschr 2009; 159: 337–341.

https://doi.org/10.1007/s10354-009-0699-z

Tavoletti G, Avallone G, Conforti C, Roccuzzo G, Maronese CA, Mattioli MA, et al. Topical ruxolitinib: a new treatment for vitiligo. J Eur Acad Dermatol Venereol 2023; 37: 2222–2230.

https://doi.org/10.1111/jdv.19162

Downloads

Published

2024-10-15

How to Cite

Weissmann, S., Babyev, A. S., Gordon, M., Golan-Tripto, I., & Horev, A. (2024). Decreased Neutrophil-to-lymphocyte Ratio in Patients with Vitiligo: National Data Analysis. Acta Dermato-Venereologica, 104, adv35406. https://doi.org/10.2340/actadv.v104.35406

Issue

Section

Articles

Categories